C
CTI Biopharma Corp
F:CEPS
CTI Biopharma Corp
F:CEPS
Price:
28
EUR
Market Cap:
€3.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
CTI Biopharma Corp
F:CEPS
|
US |
|
Wynn Macau Ltd
HKEX:1128
|
MO |
|
Samsung Electro-Mechanics Co Ltd
KRX:009150
|
KR |
|
Crossfor Co Ltd
TSE:7810
|
JP |
|
Bright Smart Securities & Commodities Group Ltd
HKEX:1428
|
HK |
|
Centerra Gold Inc
TSX:CG
|
CA |
Income Statement
Earnings Waterfall
CTI Biopharma Corp
CTI Biopharma Corp
Income Statement
CTI Biopharma Corp
CTI Biopharma Corp
Currency: USD
| Mar-2013 | Jun-2013 | Sep-2013 | Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
1
N/A
|
1
+27%
|
2
+25%
|
35
+1 827%
|
35
+1%
|
36
+3%
|
75
+109%
|
60
-20%
|
61
+2%
|
61
0%
|
23
-63%
|
16
-29%
|
50
+209%
|
56
+13%
|
60
+6%
|
57
-4%
|
22
-62%
|
37
+69%
|
34
-7%
|
25
-26%
|
35
+40%
|
14
-61%
|
13
-7%
|
27
+111%
|
16
-38%
|
16
-1%
|
18
+10%
|
3
-81%
|
3
-19%
|
2
-15%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
15
+537%
|
33
+125%
|
54
+64%
|
76
+40%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(4)
|
(4)
|
|
| Gross Profit |
1
N/A
|
1
+25%
|
2
+26%
|
35
+1 944%
|
35
+1%
|
36
+3%
|
75
+109%
|
59
-21%
|
60
+2%
|
60
0%
|
21
-65%
|
14
-33%
|
48
+238%
|
54
+13%
|
58
+8%
|
56
-4%
|
20
-64%
|
35
+73%
|
33
-7%
|
25
-24%
|
0
N/A
|
0
N/A
|
0
N/A
|
14
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
13
+566%
|
31
+127%
|
50
+65%
|
71
+41%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(102)
|
(71)
|
(72)
|
(76)
|
(85)
|
(95)
|
(111)
|
(145)
|
(147)
|
(151)
|
(151)
|
(131)
|
(133)
|
(127)
|
(128)
|
(105)
|
(93)
|
(84)
|
(64)
|
(64)
|
(60)
|
(57)
|
(59)
|
(59)
|
(54)
|
(51)
|
(47)
|
(43)
|
(41)
|
(39)
|
(38)
|
(44)
|
(57)
|
(62)
|
(75)
|
(95)
|
(116)
|
(126)
|
(132)
|
(130)
|
(125)
|
|
| Selling, General & Administrative |
(39)
|
(38)
|
(39)
|
(42)
|
(48)
|
(52)
|
(56)
|
(56)
|
(52)
|
(51)
|
(52)
|
(54)
|
(53)
|
(50)
|
(51)
|
(45)
|
(45)
|
(43)
|
(34)
|
(31)
|
(26)
|
(24)
|
(24)
|
(22)
|
(22)
|
(21)
|
(20)
|
(19)
|
(18)
|
(17)
|
(17)
|
(18)
|
(21)
|
(27)
|
(37)
|
(56)
|
(67)
|
(78)
|
(86)
|
(85)
|
(89)
|
|
| Research & Development |
(63)
|
(32)
|
(33)
|
(34)
|
(37)
|
(43)
|
(53)
|
(86)
|
(92)
|
(97)
|
(99)
|
(77)
|
(80)
|
(77)
|
(77)
|
(65)
|
(53)
|
(46)
|
(35)
|
(33)
|
(33)
|
(34)
|
(36)
|
(36)
|
(32)
|
(29)
|
(27)
|
(24)
|
(22)
|
(22)
|
(21)
|
(26)
|
(32)
|
(35)
|
(38)
|
(39)
|
(38)
|
(37)
|
(36)
|
(37)
|
(39)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(3)
|
(3)
|
(0)
|
(0)
|
0
|
0
|
0
|
5
|
5
|
5
|
5
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
(11)
|
(11)
|
(11)
|
(9)
|
3
|
|
| Operating Income |
(101)
N/A
|
(69)
+31%
|
(70)
-1%
|
(41)
+41%
|
(51)
-22%
|
(59)
-17%
|
(37)
+39%
|
(86)
-136%
|
(86)
+0%
|
(90)
-5%
|
(130)
-44%
|
(117)
+10%
|
(85)
+27%
|
(73)
+14%
|
(70)
+5%
|
(49)
+30%
|
(73)
-48%
|
(48)
+34%
|
(31)
+35%
|
(40)
-26%
|
(25)
+38%
|
(44)
-79%
|
(47)
-7%
|
(32)
+31%
|
(38)
-17%
|
(35)
+8%
|
(30)
+15%
|
(40)
-35%
|
(38)
+5%
|
(37)
+3%
|
(38)
-4%
|
(44)
-14%
|
(57)
-30%
|
(62)
-10%
|
(75)
-20%
|
(95)
-28%
|
(114)
-19%
|
(113)
+1%
|
(102)
+10%
|
(80)
+21%
|
(54)
+32%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(5)
|
(7)
|
(8)
|
(8)
|
(6)
|
(3)
|
(2)
|
(3)
|
(2)
|
(3)
|
(3)
|
(2)
|
(2)
|
(1)
|
(0)
|
(2)
|
(2)
|
(1)
|
(1)
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(8)
|
(11)
|
(13)
|
(15)
|
|
| Non-Reccuring Items |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(4)
|
(8)
|
(8)
|
(8)
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
4
|
4
|
4
|
4
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
| Pre-Tax Income |
(104)
N/A
|
(72)
+31%
|
(72)
-1%
|
(44)
+40%
|
(53)
-22%
|
(62)
-17%
|
(42)
+32%
|
(94)
-123%
|
(94)
+0%
|
(99)
-6%
|
(137)
-38%
|
(121)
+12%
|
(89)
+26%
|
(76)
+14%
|
(72)
+5%
|
(53)
+27%
|
(76)
-43%
|
(50)
+33%
|
(33)
+34%
|
(41)
-23%
|
(25)
+39%
|
(42)
-67%
|
(44)
-7%
|
(29)
+34%
|
(36)
-23%
|
(36)
+1%
|
(31)
+13%
|
(40)
-29%
|
(41)
-3%
|
(44)
-7%
|
(46)
-3%
|
(52)
-15%
|
(58)
-10%
|
(63)
-10%
|
(76)
-20%
|
(98)
-29%
|
(118)
-20%
|
(121)
-3%
|
(112)
+7%
|
(93)
+17%
|
(69)
+26%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(104)
|
(72)
|
(72)
|
(44)
|
(53)
|
(62)
|
(42)
|
(94)
|
(94)
|
(99)
|
(137)
|
(121)
|
(89)
|
(76)
|
(72)
|
(53)
|
(76)
|
(50)
|
(33)
|
(41)
|
(25)
|
(42)
|
(44)
|
(29)
|
(36)
|
(36)
|
(31)
|
(40)
|
(41)
|
(44)
|
(46)
|
(52)
|
(58)
|
(63)
|
(76)
|
(98)
|
(118)
|
(121)
|
(112)
|
(93)
|
(69)
|
|
| Income to Minority Interest |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(117)
N/A
|
(77)
+35%
|
(79)
-3%
|
(50)
+37%
|
(59)
-19%
|
(69)
-16%
|
(42)
+39%
|
(96)
-131%
|
(96)
+0%
|
(101)
-5%
|
(138)
-37%
|
(123)
+11%
|
(91)
+26%
|
(78)
+14%
|
(74)
+4%
|
(52)
+30%
|
(75)
-44%
|
(54)
+28%
|
(37)
+32%
|
(45)
-21%
|
(29)
+35%
|
(42)
-42%
|
(45)
-7%
|
(29)
+34%
|
(36)
-23%
|
(36)
+1%
|
(31)
+13%
|
(40)
-29%
|
(41)
-3%
|
(44)
-7%
|
(46)
-3%
|
(52)
-15%
|
(58)
-10%
|
(63)
-10%
|
(76)
-20%
|
(98)
-29%
|
(118)
-20%
|
(121)
-3%
|
(112)
+7%
|
(93)
+17%
|
(69)
+26%
|
|
| EPS (Diluted) |
-10.98
N/A
|
-7.11
+35%
|
-7.1
+0%
|
-3.78
+47%
|
-4.16
-10%
|
-4.75
-14%
|
-2.82
+41%
|
-5.91
-110%
|
-5.49
+7%
|
-5.74
-5%
|
-7.83
-36%
|
-5.37
+31%
|
-3.26
+39%
|
-2.78
+15%
|
-2.66
+4%
|
-0.64
+76%
|
-2.67
-317%
|
-1.7
+36%
|
-0.86
+49%
|
-1.04
-21%
|
-0.58
+44%
|
-0.71
-22%
|
-0.76
-7%
|
-0.5
+34%
|
-0.64
-28%
|
-0.63
+2%
|
-0.54
+14%
|
-0.69
-28%
|
-0.66
+4%
|
-0.6
+9%
|
-0.61
-2%
|
-0.7
-15%
|
-0.77
-10%
|
-0.68
+12%
|
-0.81
-19%
|
-1
-23%
|
-1.18
-18%
|
-1.11
+6%
|
-0.92
+17%
|
-0.72
+22%
|
-0.52
+28%
|
|
Switch to:
Switch to:
See Also
Discover More
